May 12 (Reuters) - Isomorphic Labs, an artificial intelligence-driven drug discovery company, said on Wednesday it has raised ...

The proceeds will be used to accelerate Isomorphic Labs’ pipeline of therapeutic programmes and further develop its IsoDDE AI drug design engine.

In 2024, DeepMind and Isomorphic Labs released a significantly improved successor to the model. AlphaFold 3 delivers a more ...

Alphabet-backed start-up Isomorphic Labs has added to the lustre attached to its AI-powered drug discovery engine by raising ...

Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline. LONDON, May 12, 2026 /CNW/ -- Isomorphic ...

If any proof was needed that big money is still available for AI drug development, look no further than the ten-figure series B hauled in by Isomorphic Labs. The London-based AI drug discovery firm ...

Isomorphic Labs president Max Jaderberg said at WIRED Health in London that the startup has built a “broad and exciting pipeline of new medicines.” ...

Isomorphic Labs secures $2.1 billion in funding to accelerate its AI-powered drug discovery engine and scale pharmaceutical ...

Sir Demis Hassabis has hailed a multi-billion-dollar investment in the startup he founded which was spun out of Google ...

Advanced discussions are underway to raise more than $2B for Isomorphic Labs, an AI-driven drug discovery firm spun out of Alphabet's (GOOG) Google DeepMind, as part of a new funding round, Bloomberg ...

London-based Isomorphic Labs Ltd., a drug discovery-focused artificial intelligence startup that was spun out of Google LLC’s DeepMind unit just over two years ago, today announced key partnerships ...

Isomorphic Labs, a London-based spin-out of Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL) Google's AI R&D division DeepMind, has announced strategic partnerships with Eli Lilly And Co (NYSE:LLY) and ...